10-Q 1 scl-20220630.htm 10-Q scl-20220630
000086187812-31June 30, 20222022Q2FALSESTERICYCLE INC.00008618782022-01-012022-06-3000008618782022-08-02xbrli:shares00008618782022-04-012022-06-30iso4217:USD00008618782021-04-012021-06-3000008618782021-01-012021-06-30iso4217:USDxbrli:shares00008618782022-06-3000008618782021-12-3100008618782020-12-3100008618782021-06-300000861878us-gaap:CommonStockMember2022-03-310000861878us-gaap:AdditionalPaidInCapitalMember2022-03-310000861878us-gaap:RetainedEarningsMember2022-03-310000861878us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000861878us-gaap:NoncontrollingInterestMember2022-03-3100008618782022-03-310000861878us-gaap:RetainedEarningsMember2022-04-012022-06-300000861878us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000861878us-gaap:NoncontrollingInterestMember2022-04-012022-06-300000861878us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300000861878us-gaap:CommonStockMember2022-06-300000861878us-gaap:AdditionalPaidInCapitalMember2022-06-300000861878us-gaap:RetainedEarningsMember2022-06-300000861878us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000861878us-gaap:NoncontrollingInterestMember2022-06-300000861878us-gaap:CommonStockMember2021-03-310000861878us-gaap:AdditionalPaidInCapitalMember2021-03-310000861878us-gaap:RetainedEarningsMember2021-03-310000861878us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000861878us-gaap:NoncontrollingInterestMember2021-03-3100008618782021-03-310000861878us-gaap:RetainedEarningsMember2021-04-012021-06-300000861878us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000861878us-gaap:NoncontrollingInterestMember2021-04-012021-06-300000861878us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300000861878us-gaap:CommonStockMember2021-06-300000861878us-gaap:AdditionalPaidInCapitalMember2021-06-300000861878us-gaap:RetainedEarningsMember2021-06-300000861878us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000861878us-gaap:NoncontrollingInterestMember2021-06-300000861878us-gaap:CommonStockMember2021-12-310000861878us-gaap:AdditionalPaidInCapitalMember2021-12-310000861878us-gaap:RetainedEarningsMember2021-12-310000861878us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000861878us-gaap:NoncontrollingInterestMember2021-12-310000861878us-gaap:RetainedEarningsMember2022-01-012022-06-300000861878us-gaap:NoncontrollingInterestMember2022-01-012022-06-300000861878us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300000861878us-gaap:CommonStockMember2022-01-012022-06-300000861878us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300000861878us-gaap:CommonStockMember2020-12-310000861878us-gaap:AdditionalPaidInCapitalMember2020-12-310000861878us-gaap:RetainedEarningsMember2020-12-310000861878us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000861878us-gaap:NoncontrollingInterestMember2020-12-310000861878us-gaap:RetainedEarningsMember2021-01-012021-06-300000861878us-gaap:NoncontrollingInterestMember2021-01-012021-06-300000861878us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300000861878us-gaap:CommonStockMember2021-01-012021-06-300000861878us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300000861878srcl:RegulatedWasteAndComplianceServicesMember2022-04-012022-06-300000861878srcl:RegulatedWasteAndComplianceServicesMember2021-04-012021-06-300000861878srcl:RegulatedWasteAndComplianceServicesMember2022-01-012022-06-300000861878srcl:RegulatedWasteAndComplianceServicesMember2021-01-012021-06-300000861878srcl:SecureInformationDestructionServicesMember2022-04-012022-06-300000861878srcl:SecureInformationDestructionServicesMember2021-04-012021-06-300000861878srcl:SecureInformationDestructionServicesMember2022-01-012022-06-300000861878srcl:SecureInformationDestructionServicesMember2021-01-012021-06-300000861878srcl:RegulatedWasteAndComplianceServicesMembersrcl:NorthAmericaSegmentMember2022-04-012022-06-300000861878srcl:RegulatedWasteAndComplianceServicesMembersrcl:NorthAmericaSegmentMember2021-04-012021-06-300000861878srcl:RegulatedWasteAndComplianceServicesMembersrcl:NorthAmericaSegmentMember2022-01-012022-06-300000861878srcl:RegulatedWasteAndComplianceServicesMembersrcl:NorthAmericaSegmentMember2021-01-012021-06-300000861878srcl:SecureInformationDestructionServicesMembersrcl:NorthAmericaSegmentMember2022-04-012022-06-300000861878srcl:SecureInformationDestructionServicesMembersrcl:NorthAmericaSegmentMember2021-04-012021-06-300000861878srcl:SecureInformationDestructionServicesMembersrcl:NorthAmericaSegmentMember2022-01-012022-06-300000861878srcl:SecureInformationDestructionServicesMembersrcl:NorthAmericaSegmentMember2021-01-012021-06-300000861878srcl:NorthAmericaSegmentMember2022-04-012022-06-300000861878srcl:NorthAmericaSegmentMember2021-04-012021-06-300000861878srcl:NorthAmericaSegmentMember2022-01-012022-06-300000861878srcl:NorthAmericaSegmentMember2021-01-012021-06-300000861878srcl:RegulatedWasteAndComplianceServicesMembersrcl:InternationalSegmentsMember2022-04-012022-06-300000861878srcl:RegulatedWasteAndComplianceServicesMembersrcl:InternationalSegmentsMember2021-04-012021-06-300000861878srcl:RegulatedWasteAndComplianceServicesMembersrcl:InternationalSegmentsMember2022-01-012022-06-300000861878srcl:RegulatedWasteAndComplianceServicesMembersrcl:InternationalSegmentsMember2021-01-012021-06-300000861878srcl:SecureInformationDestructionServicesMembersrcl:InternationalSegmentsMember2022-04-012022-06-300000861878srcl:SecureInformationDestructionServicesMembersrcl:InternationalSegmentsMember2021-04-012021-06-300000861878srcl:SecureInformationDestructionServicesMembersrcl:InternationalSegmentsMember2022-01-012022-06-300000861878srcl:SecureInformationDestructionServicesMembersrcl:InternationalSegmentsMember2021-01-012021-06-300000861878srcl:InternationalSegmentsMember2022-04-012022-06-300000861878srcl:InternationalSegmentsMember2021-04-012021-06-300000861878srcl:InternationalSegmentsMember2022-01-012022-06-300000861878srcl:InternationalSegmentsMember2021-01-012021-06-300000861878us-gaap:OtherCurrentAssetsMember2022-06-300000861878us-gaap:OtherCurrentAssetsMember2021-12-310000861878us-gaap:OtherNoncurrentAssetsMember2022-06-300000861878us-gaap:OtherNoncurrentAssetsMember2021-12-310000861878us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembersrcl:InternationalSegmentsMembersrcl:JapanOperatingUnitMember2021-09-010000861878us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembersrcl:CanadaEnvironmentalSolutionsOperationsMembersrcl:NorthAmericaSegmentMember2021-12-010000861878srcl:MidwestBasedRegulatedWasteBusinessMember2022-04-012022-06-300000861878srcl:MidwestBasedRegulatedWasteBusinessMember2022-06-300000861878srcl:MidwestBasedRegulatedWasteBusinessMemberus-gaap:CustomerRelationshipsMember2022-06-300000861878srcl:CreditAgreementAmendedSept2021Membersrcl:SeniorCreditFacilityDueSeptemberTwentyTwentySixMemberus-gaap:LineOfCreditMember2022-06-300000861878srcl:CreditAgreementAmendedSept2021Membersrcl:SeniorCreditFacilityDueSeptemberTwentyTwentySixMemberus-gaap:LineOfCreditMember2021-12-310000861878srcl:CreditAgreementAmendedSept2021Membersrcl:TermLoanFacilityDueTwentyTwentySixMemberus-gaap:LineOfCreditMember2022-06-300000861878srcl:CreditAgreementAmendedSept2021Membersrcl:TermLoanFacilityDueTwentyTwentySixMemberus-gaap:LineOfCreditMember2021-12-310000861878us-gaap:SeniorNotesMembersrcl:SeniorNotesFacilityDueTwentyTwentyFourMember2022-06-300000861878us-gaap:SeniorNotesMembersrcl:SeniorNotesFacilityDueTwentyTwentyFourMember2021-12-310000861878us-gaap:SeniorNotesMembersrcl:SeniorNotesFacilityDueTwentyTwentyNineMember2022-06-300000861878us-gaap:SeniorNotesMembersrcl:SeniorNotesFacilityDueTwentyTwentyNineMember2021-12-310000861878srcl:NotesWeightedAverageMaturityTwoPointThreeYearsAndTwoPointFiveYearsMembersrcl:PromissoryNotesAndDeferredConsiderationMember2022-01-012022-06-300000861878srcl:NotesWeightedAverageMaturityTwoPointThreeYearsAndTwoPointFiveYearsMembersrcl:PromissoryNotesAndDeferredConsiderationMember2021-01-012021-12-310000861878srcl:NotesWeightedAverageMaturityTwoPointFourNineAndTwoPointSevenFourYearsMembersrcl:PromissoryNotesAndDeferredConsiderationMember2022-06-300000861878srcl:NotesWeightedAverageMaturityTwoPointFourNineAndTwoPointSevenFourYearsMembersrcl:PromissoryNotesAndDeferredConsiderationMember2021-12-310000861878srcl:DebtWeightedAverageMaturityOnePointFourYearsAndOnePointSixYearsMembersrcl:ForeignLongTermDebtMember2022-01-012022-06-300000861878srcl:DebtWeightedAverageMaturityOnePointFourYearsAndOnePointSixYearsMembersrcl:ForeignLongTermDebtMember2021-01-012021-12-310000861878srcl:ForeignLongTermDebtMembersrcl:DebtWeightedAverageMaturityOnePointSixAndOnePointNineYearsMember2022-06-300000861878srcl:ForeignLongTermDebtMembersrcl:DebtWeightedAverageMaturityOnePointSixAndOnePointNineYearsMember2021-12-310000861878us-gaap:FairValueInputsLevel2Member2022-06-300000861878us-gaap:FairValueInputsLevel2Member2021-12-310000861878srcl:CreditAgreementAmendedSept2021Membersrcl:SeniorCreditFacilityDueSeptemberTwentyTwentySixMemberus-gaap:LineOfCreditMember2022-01-012022-06-30xbrli:pure0000861878srcl:CreditAgreementAmendedSept2021Membersrcl:SeniorCreditFacilityDueSeptemberTwentyTwentySixMemberus-gaap:LineOfCreditMember2021-01-012021-12-310000861878srcl:CreditAgreementAmendedSept2021Membersrcl:TermLoanFacilityDueTwentyTwentySixMemberus-gaap:LineOfCreditMember2022-01-012022-06-300000861878srcl:CreditAgreementAmendedSept2021Membersrcl:TermLoanFacilityDueTwentyTwentySixMemberus-gaap:LineOfCreditMember2021-01-012021-12-310000861878us-gaap:SeniorNotesMembersrcl:SeniorNotesFacilityDueTwentyTwentyFourMember2022-06-300000861878us-gaap:SeniorNotesMembersrcl:SeniorNotesFacilityDueTwentyTwentyFourMember2021-12-310000861878srcl:CreditAgreementAmendedSept2021Memberus-gaap:LineOfCreditMember2021-07-012021-09-300000861878srcl:CreditAgreementAmendedSept2021Memberus-gaap:LineOfCreditMember2021-10-012021-12-310000861878srcl:CreditAgreementAmendedSept2021Memberus-gaap:LineOfCreditMember2022-01-012022-03-310000861878srcl:CreditAgreementAmendedSept2021Membersrcl:ConsolidatedLeverageRatioPeriodOneMemberus-gaap:LineOfCreditMember2022-01-012022-06-300000861878srcl:CreditAgreementAmendedSept2021Membersrcl:ConsolidatedLeverageRatioPeriodTwoMemberus-gaap:LineOfCreditMember2022-01-012022-06-300000861878srcl:CreditAgreementAmendedSept2021Membersrt:ScenarioForecastMemberus-gaap:LineOfCreditMember2022-10-012022-12-310000861878srcl:CreditAgreementAmendedSept2021Memberus-gaap:LineOfCreditMember2022-04-012022-04-300000861878srcl:CreditAgreementAmendedSept2021Memberus-gaap:LineOfCreditMember2022-06-300000861878srcl:SeniorCreditFacilityDueSeptemberTwentyTwentySixMemberus-gaap:LineOfCreditMember2022-06-300000861878srcl:SeniorCreditFacilityDueSeptemberTwentyTwentySixMemberus-gaap:LineOfCreditMember2021-12-310000861878us-gaap:EmployeeStockOptionMember2022-04-012022-06-300000861878us-gaap:EmployeeStockOptionMember2021-04-012021-06-300000861878us-gaap:EmployeeStockOptionMember2022-01-012022-06-300000861878us-gaap:EmployeeStockOptionMember2021-01-012021-06-300000861878us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300000861878us-gaap:RestrictedStockUnitsRSUMember2021-04-012021-06-300000861878us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300000861878us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-30srcl:segment0000861878us-gaap:AllOtherSegmentsMember2022-04-012022-06-300000861878us-gaap:AllOtherSegmentsMember2021-04-012021-06-300000861878us-gaap:AllOtherSegmentsMember2022-01-012022-06-300000861878us-gaap:AllOtherSegmentsMember2021-01-012021-06-300000861878srcl:DepartmentOfJusticeGovernmentInvestigationsMembersrcl:DepartmentOfJusticeMember2022-04-202022-04-200000861878srcl:DepartmentOfJusticeGovernmentInvestigationsMembersrcl:BrazilianAuthoritiesMember2022-04-202022-04-200000861878srcl:SecuritiesAndExchangeCommissionGovernmentInvestigationsMembersrcl:USSecuritiesAndExchangeCommissionMember2022-04-202022-04-200000861878srcl:SecuritiesAndExchangeCommissionGovernmentInvestigationsMembersrcl:BrazilianAuthoritiesMember2022-04-202022-04-200000861878srcl:BrazilianGovernmentInvestigationsMembersrcl:BrazilianAuthoritiesMember2022-04-202022-04-200000861878srcl:BrazilianGovernmentInvestigationsMembersrcl:USSecuritiesAndExchangeCommissionAndDepartmentOfJusticeMember2022-04-202022-04-200000861878srcl:GovernmentInvestigationsMember2021-12-310000861878srcl:GovernmentInvestigationsMember2022-01-012022-06-300000861878srcl:GovernmentInvestigationsMembersrcl:USSecuritiesAndExchangeCommissionDepartmentOfJusticeAndBrazilianAuthoritiesMember2022-04-012022-06-30

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________________
FORM 10-Q
________________________________________________________
[Mark One]
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 1-37556
________________________________________________________
scl-20220630_g1.gif
________________________________________________________
Delaware36-3640402
(State or other jurisdiction of incorporation or organization)(IRS Employer Identification Number)
2355 Waukegan Road
Bannockburn, Illinois 60015
(Address of principal executive offices, including zip code)
(847) 367-5910
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareSRCLNasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Smaller reporting company
Accelerated filer ☐
Emerging growth company
Non-accelerated filer ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No x
On August 2, 2022, there were 92,180,327 shares of the Registrant’s Common Stock outstanding.


scl-20220630_g2.jpg
Table of Contents
Page No.
11 
20 
30 
30 
31 
31 
31 
32 
33 

2022 Q2 10-Q Report
Stericycle, Inc. ●
3

Glossary of Defined Terms
Unless the context requires otherwise, the “Company”, “Stericycle”, “we”, “us” or “our” refers to Stericycle, Inc. on a consolidated basis. The Company also uses several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
AbbreviationDescription
2021 Form 10-KAnnual report on Form 10-K for the year ended December 31, 2021
Adjusted Income from OperationsIncome from Operations adjusted for certain items discussed in Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
AICPAAmerican Institute of Certified Public Accountants
ASCAccounting Standards Codification
ASUAccounting Standards Update
CDCU.S. Centers for Disease Control and Prevention
Credit Agreement Defined Debt Leverage Ratio
As of any date of determination, the ratio of (a) (i) Consolidated Funded Indebtedness as of such date minus (ii) Unrestricted Cash as of such date to (b) Consolidated EBITDA for the period of four fiscal quarters most recently ended on or prior to such date
CORCost of Revenues
COVID-19The global novel coronavirus disease 2019 outbreak, which the World Health Organization declared as to be a pandemic
Credit AgreementCredit Agreement dated as of September 30, 2022 and First Amendment dated April 26, 2022, among the Company and certain subsidiaries as borrowers. Bank of America, N.A., as administrative agent, swing line lender, a lender and a letter of credit issuer and the other lenders party thereto, as amended
Credit FacilityThe Company's $1.2 billion credit facility due in September of 2026 granted under the terms of the Credit Agreement
DEAU.S. Drug Enforcement Administration. The DEA is a division of the U.S. Department of Justice. It is the federal agency which regulates the manufacture, dispensing, storage, and shipment of controlled substances including medications with human abuse potential
DOJU.S. Department of Justice
Domestic Environmental SolutionsHazardous Waste Solutions and Manufacturing and Industrial Services
DOTU.S. Department of Transportation
DSODays Sales Outstanding, defined as the average number of days that it takes a company to collect payment after revenue has been recorded, computed as the trailing twelve months of Revenues for the period ended DSO, divided by the Accounts Receivable balance at the end of the period
DTSCU.S. Department of Toxic Substances Control
EBITDAEarnings Before Interest, Taxes, Depreciation & Amortization. Another common financial term utilized by Stericycle to analyze the core profitability of the business before interest, tax, depreciation and amortization
EPAU.S. Environmental Protection Agency
ERPEnterprise Resource Planning
Exchange ActU.S. Securities Exchange Act of 1934
FASBFinancial Accounting Standards Board
FCPAU.S. Foreign Corrupt Practices Act
FCPA SettlementFCPA Settlement with the Securities and Exchange Commission, the Department of Justice and Brazilian authorities of approximately $90.0 million
InternationalOperating segment including Europe, Middle East, Asia Pacific and Latin America Business operations outside of North America
IRSU.S. Internal Revenue Service
North AmericaOperating segment in North America, including U.S., Canada and Puerto Rico
OSHAU.S. Occupational Safety and Health Act of 1970
Other CostsRepresents corporate enabling and shared services costs, annual incentive and stock-based compensation
PFAPre-filing agreement with the U.S. Internal Revenue Service
Purchase AgreementStock Purchase Agreement, dated as of February 6, 2020, by and between Stericycle, Inc., and the Harsco Corporation and CEI Holding LLC, a Delaware limited liability company and subsidiary of Harsco Corporation
PSUPerformance-based Restricted Stock Unit
RSURestricted Stock Unit
RTOReturn to Office
RWCSRegulated Waste and Compliance Services, a business unit that provides regulated medical waste services and patient engagement
SECU.S. Securities and Exchanges Commission
Senior Notes5.375% ($600.0 million) Senior Notes due July 2024 and 3.875% ($500.0 million) Senior Notes due January 2029
SG&ASelling, General and Administrative expenses
SIDSecure Information Destruction Services, a business unit that provides confidential customer material shredding services and recycling of shredded paper
SOPSorted Office Paper
SQ SettlementSmall quantity medical waste customers class action settlement of $295.0 million
Term FacilityAggregate amount of commitments made by any lender under the terms of the Credit Agreement
Term LoansAdvances made by any lender under the Term Facility
U.S.United States of America
U.S. GAAPU.S. Generally Accepted Accounting Principles
2022 Q2 10-Q Report
Stericycle, Inc. ●
4

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)

STERICYCLE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
(Unaudited)
In millions, except per share data
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Revenues$679.8 $672.7 $1,344.0 $1,340.7 
Cost of revenues419.3 403.6 839.0 810.2 
Gross profit260.5 269.1 505.0 530.5 
Selling, general and administrative expenses222.4 213.5 461.0 415.8 
Income from operations38.1 55.6 44.0 114.7 
Interest expense, net(18.5)(17.9)(34.8)(36.3)
Other (expense) income, net(0.7)0.7 (1.5) 
Income before income taxes18.9 38.4 7.7 78.4 
Income tax expense(8.4)(9.1)(11.3)(22.9)
Net income (loss)10.5 29.3 (3.6)55.5 
Net income attributable to noncontrolling interests  (0.2)(0.1)
Net income (loss) attributable to Stericycle, Inc. common shareholders$10.5 $29.3 $(3.8)$55.4 
Earnings (loss) per common share attributable to Stericycle, Inc. common shareholders
Basic$0.11 $0.32 $(0.04)$0.60 
Diluted$0.11 $0.32 $(0.04)$0.60 
Weighted average number of common shares outstanding:
Basic92.1 91.8 92.0 91.7 
Diluted92.2 92.1 92.0 92.1 
See accompanying Notes to Condensed Consolidated Financial Statements.
2022 Q2 10-Q Report
Stericycle, Inc. ●
5

STERICYCLE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(Unaudited)
In millions
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Net income (loss)$10.5 $29.3 $(3.6)$55.5 
Other comprehensive (loss) income:
Currency translation adjustments(46.0)6.7 (54.9)(6.4)
Total other comprehensive (loss) income(46.0)6.7 (54.9)(6.4)
 
Comprehensive (loss) income(35.5)36.0 (58.5)49.1 
Less: comprehensive loss (income) attributable to noncontrolling interests(0.1)0.1 (0.3) 
Comprehensive (loss) income attributable to Stericycle, Inc. common shareholders$(35.4)$35.9 $(58.2)$49.1 
See accompanying Notes to Condensed Consolidated Financial Statements.

2022 Q2 10-Q Report
Stericycle, Inc. ●
6

STERICYCLE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
In millions, except per share data
June 30, 2022December 31, 2021
ASSETS
Current Assets:
Cash and cash equivalents$45.9 $55.6 
Accounts receivable, less allowance for doubtful accounts of $54.4 in 2022 and $43.3 in 2021
466.2 420.4 
Prepaid expenses35.4 45.6 
Other current assets49.4 53.9 
Total Current Assets596.9 575.5 
Property, plant and equipment, less accumulated depreciation of $681.2 in 2022 and $658.5 in 2021
719.8 711.0 
Operating lease right-of-use assets357.1 344.8 
Goodwill2,784.3 2,815.7 
Intangible assets, less accumulated amortization of $787.7 in 2022 and $736.6 in 2021
887.4 964.5 
Other assets62.5 61.6 
Total Assets$5,408.0 $5,473.1 
LIABILITIES AND EQUITY
Current Liabilities:
Current portion of long-term debt$16.5 $19.9 
Bank overdrafts1.0 1.6 
Accounts payable207.1 218.9 
Accrued liabilities256.2 359.6 
Operating lease liabilities85.4 85.5 
Other current liabilities52.4 46.2 
Total Current Liabilities618.6 731.7 
Long-term debt, net1,676.3 1,589.8 
Long-term operating lease liabilities292.2 279.8 
Deferred income taxes412.9 411.0 
Long-term taxes payable17.3 19.1 
Other liabilities37.0 38.9 
Total Liabilities3,054.3 3,070.3 
Commitments and contingencies
EQUITY
Common stock (par value $0.01 per share, 120.0 shares authorized, 92.1 and 91.9 issued and outstanding in 2022 and 2021, respectively)
0.9 0.9 
Additional paid-in capital1,271.2 1,261.8 
Retained earnings1,351.0 1,354.8 
Accumulated other comprehensive loss(273.2)(218.8)
Total Stericycle, Inc.’s Equity2,349.9 2,398.7 
Noncontrolling interests3.8 4.1 
Total Equity2,353.7 2,402.8 
Total Liabilities and Equity$5,408.0 $5,473.1 
See accompanying Notes to Condensed Consolidated Financial Statements.
2022 Q2 10-Q Report
Stericycle, Inc. ●
7

STERICYCLE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
In millions
Six Months Ended June 30,
20222021
OPERATING ACTIVITIES:
Net (loss) income$(3.6)$55.5 
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation54.3 50.4 
Intangible amortization63.2 59.9 
Stock-based compensation expense12.6 12.2 
Deferred income taxes5.2 (8.8)
Loss on disposal of property plant and equipment and other charges0.3  
Other, net1.6 2.2 
Changes in operating assets and liabilities:
Accounts receivable(53.4)(22.8)
Prepaid expenses10.0 30.9 
Accounts payable(12.5)(7.2)
Accrued liabilities(91.6)(11.0)
Other assets and liabilities(4.5)(11.5)
Net cash from operating activities(18.4)149.8 
INVESTING ACTIVITIES:
Capital expenditures(70.0)(59.7)
Proceeds (payments) from divestiture of businesses, net1.6 (0.7)
Other, net0.8 2.0 
Net cash from investing activities(67.6)(58.4)
FINANCING ACTIVITIES:
Repayments of long-term debt and other obligations(8.4)(11.6)
Repayments of foreign bank debt(0.1)(0.2)
Repayments of term loan (104.3)
Proceeds from credit facility732.5 648.0 
Repayments of credit facility(637.9)(610.6)
(Repayment of) proceeds from bank overdrafts, net(0.6)2.3 
Payments of finance lease obligations(1.3)(2.0)
Proceeds from issuance of common stock, net of (payments of) taxes from withheld shares(5.2)(3.6)
Payments to noncontrolling interest (0.6)
Net cash from financing activities79.0 (82.6)
Effect of exchange rate changes on cash and cash equivalents(2.7)(0.4)
Net change in cash and cash equivalents(9.7)8.4 
Cash and cash equivalents at beginning of period55.6 53.3 
Cash and cash equivalents at end of period$45.9 $61.7 
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid, net of capitalized interest$31.9 $23.0 
Income taxes paid (refunded), net$4.0 $8.1 
Capital expenditures in Accounts payable$30.8 $14.9 
See accompanying Notes to Condensed Consolidated Financial Statements.
2022 Q2 10-Q Report
Stericycle, Inc. ●
8

STERICYCLE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)

In millions
Stericycle, Inc. Equity
Common StockAdditional Paid-In
Capital
Retained EarningsAccumulated Other
Comprehensive Loss
Noncontrolling InterestsTotal Equity
SharesAmount
Balance as of April 1, 202292.1 $0.9 $1,263.4 $1,340.5 $(227.3)$3.9 $2,381.4 
Net income— — — 10.5 — — 10.5 
Currency translation adjustment— — — — (45.9)(0.1)(46.0)
Issuance of common stock for incentive stock programs, net of (payments of) taxes from withheld shares— — — — — — — 
Stock-based compensation expense— — 7.8 — — — 7.8 
Balance as of June 30, 202292.1 $0.9 $1,271.2 $1,351.0 $(273.2)$3.8 $2,353.7 
In millions
Stericycle, Inc. Equity
Common StockAdditional Paid-In
Capital
Retained EarningsAccumulated Other
Comprehensive Loss
Noncontrolling InterestsTotal Equity
SharesAmount
Balance as of April 1, 202191.8 $0.9 $1,235.9 $1,408.7 $(200.3)$3.6 $2,448.8 
Net income — — — 29.3 — — 29.3 
Currency translation adjustment— — — — 6.6 0.1 6.7 
Issuance of common stock for incentive stock programs, net of (payments of) taxes from withheld shares— — 1.6 — — — 1.6 
Stock-based compensation expense— — 7.1 — — — 7.1 
Balance as of June 30, 202191.8 $0.9 $1,244.6 $1,438.0 $(193.7)$3.7 $2,493.5 
See accompanying Notes to Condensed Consolidated Financial Statements.
2022 Q2 10-Q Report
Stericycle, Inc. ●
9

STERICYCLE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)

In millions
Stericycle, Inc. Equity
Common StockAdditional Paid-In
Capital
Retained EarningsAccumulated Other
Comprehensive Loss
Noncontrolling InterestsTotal Equity
SharesAmount
Balance as of December 31, 202191.9 $0.9 $1,261.8 $1,354.8 $(218.8)$4.1 $2,402.8 
Net (loss) income— — — (3.8)— 0.2 (3.6)
Currency translation adjustment— — — — (54.4)(0.5)(54.9)
Issuance of common stock for incentive stock programs, net of (payments of) taxes from withheld shares0.2 — (3.2)— — — (3.2)
Stock-based compensation expense— — 12.6 — — — 12.6 
Changes in noncontrolling interest— — — — — — — 
Balance as of June 30, 202292.1 $0.9 $1,271.2 $1,351.0 $(273.2)$3.8 $2,353.7 
In millions
Stericycle, Inc. Equity
Common StockAdditional Paid-In
Capital
Retained EarningsAccumulated Other
Comprehensive Loss
Noncontrolling InterestsTotal Equity
SharesAmount
Balance as of December 31, 202091.6 $0.9 $1,234.0 $1,382.6 $(187.4)$4.3 $2,434.4 
Net income — — 55.4 — 0.1 55.5 
Currency translation adjustment— — — — (6.3)(0.1)(6.4)
Issuance of common stock for incentive stock programs, net of (payments of) taxes from withheld shares0.2 — (1.6)— — — (1.6)
Stock-based compensation expense— — 12.2 — — — 12.2 
Changes in noncontrolling interest— — — — — (0.6)(0.6)
Balance as of June 30, 202191.8 $0.9 $1,244.6 $1,438.0 $(193.7)$3.7 $2,493.5 
See accompanying Notes to Condensed Consolidated Financial Statements.
2022 Q2 10-Q Report
Stericycle, Inc. ●
10


STERICYCLE, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Summary of Significant Accounting Policies
Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of Stericycle, Inc. and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company's Condensed Consolidated Financial Statements were prepared in accordance with U.S. GAAP and include the assets, liabilities, revenues, and expenses of all wholly owned subsidiaries and majority-owned subsidiaries over which the Company exercises control. Outside shareholders' interests in subsidiaries are shown on the Condensed Consolidated Financial Statements as “Noncontrolling interests”.
The accompanying unaudited Condensed Consolidated Financial Statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021, have been prepared pursuant to the rules and regulations of the SEC for interim reporting and, therefore, do not include all information and footnote disclosures normally included in audited financial statements prepared in conformity with U.S. GAAP. In the opinion of management, however, all adjustments, consisting of normal recurring adjustments necessary to present fairly the results of operations, financial position and cash flows have been made. These Condensed Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and notes thereto included in the 2021 Form 10-K. The results of operations for any interim period are not necessarily indicative of the results of operations to be expected for the full year or any other period.
Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Some areas where the Company makes estimates include allowance for doubtful accounts, credit memo reserves, contingent liabilities, asset retirement obligations, stock compensation expense, income tax assets and liabilities, accrued employee health and welfare benefits, accrued auto and workers’ compensation self-insured claims, leases, acquisition related long-lived assets, goodwill and held for sale impairment valuations. Such estimates are based on historical trends and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates.
Accounting Standards Issued But Not Yet Adopted: Recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the AICPA and SEC did not, or are not expected to, have a material impact on our Condensed Consolidated Financial Statements.

NOTE 2 — REVENUES FROM CONTRACTS WITH CUSTOMERS
The Company provides RWCS, which provide collection and processing of regulated and specialized waste, including medical, pharmaceutical and hazardous waste, for disposal and compliance programs and communication solutions, and SID Services, which provide for the collection of personal and confidential information for secure destruction and recycling of shredded paper.
The Company’s customers typically enter into a contract for the provision of services on a regular and scheduled basis (e.g. weekly or monthly) or on an as needed basis (e.g. one-time service) over the contract term. Under the contract terms, the Company receives fees based on a monthly, quarterly or annual rate and/or fees based on contractual rates depending upon measures including the volume, weight, and type of waste, number and size of containers collected, weight and type of shredded paper, and number of call minutes.
Amounts are invoiced based on the terms of the underlying contract either on a regular basis (e.g. monthly or quarterly) or as services are performed and are generally due within a short period of time after invoicing based upon normal terms and conditions for our business type and the geography of the services performed.
2022 Q2 10-Q Report
Stericycle, Inc. ●
11

Disaggregation of Revenues
The following table presents revenues disaggregated by service and reportable segments:
In millions
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Revenue by Service
Regulated Waste and Compliance Services$448.4 $463.0 $901.2 $936.6 
Secure Information Destruction Services231.4 209.7 442.8 404.1 
Total Revenues$679.8 $672.7 $1,344.0 $1,340.7 
North America
Regulated Waste and Compliance Services$365.6 $362.2 $727.8 $729.0 
Secure Information Destruction Services203.0 180.4 384.5 347.3 
Total North America Segment$568.6 $542.6 $1,112.3 $1,076.3 
International
Regulated Waste and Compliance Services$82.8 $100.8 $173.4 $207.6 
Secure Information Destruction Services28.4 29.3 58.3 56.8 
Total International Segment$111.2 $130.1 $231.7 $264.4 
Contract Liabilities
Contract liabilities at June 30, 2022 and December 31, 2021, were $9.5 million and $9.0 million, respectively. Substantially all of the contract liabilities as of June 30, 2022, are expected to be recognized in Revenues, as the amounts are earned, which will be over the next 12 months.
Contract Acquisition Costs
The Company’s incremental direct costs of obtaining a contract, which consist primarily of sales incentives, are deferred and amortized to SG&A over a weighted average estimated period of benefit of 6.5 years.
During the three months ended June 30, 2022 and 2021, the Company amortized $3.5 million and $3.1 million, respectively, of deferred sales incentives to SG&A. During the six months ended June 30, 2022 and 2021, the Company amortized $7.0 million and $6.1 million, respectively, of deferred sales incentives to SG&A.
Total contract acquisition costs, net of accumulated amortization, were classified as follows:
In millions
 June 30, 2022December 31, 2021
Other current assets$13.4 $12.4 
Other assets36.9 34.3 
Total contract acquisition costs$50.3 $46.7 
Allowance for Doubtful Accounts
The Company estimates its allowance for doubtful accounts based on past collection history and specific risks identified among uncollected amounts, as well as management’s expectation of future economic conditions. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Past-due receivable balances are generally written off when the Company’s collection efforts have been exhausted.


2022 Q2 10-Q Report
Stericycle, Inc. ●
12

The changes in allowance for doubtful accounts were reported as follows:
In millions
Six Months Ended June 30,
20222021
Beginning Balance$43.3 $56.2 
Bad debt expense, net of recoveries16.6 1.8 
Write-offs(5.9)(9.4)
Other changes0.4 0.5 
Ending Balance$54.4 $49.1 

NOTE 3 — DIVESTITURES
On September 1, 2021, the Company completed the sale of its operations in Japan for cash proceeds of $11.3 million reported in International. On December 1, 2021, the Company completed the sale of its Environmental Solutions operations in Canada for cash proceeds of $24.4 million reported in North America. The results of operations of these divested businesses have been excluded from our Condensed Consolidated Financial Statements from the date of the divestitures.

NOTE 4 — ACQUISITION
The Company acquired a midwest-based regulated waste business in North America on December 31, 2021, which is considered to be complementary to existing operations and aligns with the Company’s portfolio optimization strategy.
The purchase price consideration of $42.8 million and the purchase price allocation was finalized in the second quarter of 2022. The final acquisition date fair value of the total consideration transferred included $10.5 million in cash, $21.3 million in promissory notes, and $11.0 million in deferred consideration. The purchase price consideration was allocated to the assets and liabilities based on fair value as of the acquisition date, with the excess of the purchase price consideration over the net assets acquired of $23.7 million recorded as goodwill based on the strategic benefits to be achieved and is deductible for tax purposes. The Company used a third party specialist to determine the fair value of tangible and intangible assets, which primarily consisted of customer relationships of $17.5 million. The Company recorded final fair value measurement adjustments in the second quarter of 2022, which included a decrease of $2.5 million in intangible assets, a $0.2 million increase in fixed assets, and a $1.7 million increase in goodwill.

2022 Q2 10-Q Report
Stericycle, Inc. ●
13

NOTE 5 — LONG-TERM DEBT
The Company’s long-term debt consisted of the following:
In millions
June 30, 2022December 31, 2021
$1.2 billion Credit Facility, due in 2026
$339.7 $247.0 
$200 million Term Loan, due in 2026
200.0 200.0 
$600 million Senior Notes, due in 2024
600.0 600.0 
$500 million Senior Notes, due in 2029
500.0 500.0 
Promissory notes and deferred consideration weighted average maturity of 3.7 years at 2022 and 3.7 years at 2021
45.6 54.6 
Foreign bank debt weighted average maturity 5.5 years at 2022 and 6.0 years at 2021
0.5 0.7 
Obligations under finance leases19.8 21.4 
Total debt1,705.6 1,623.7 
Less: current portion of total debt16.5 19.9 
Less: unamortized debt issuance costs12.8 14.0 
Long-term portion of total debt$1,676.3 $1,589.8 
The estimated fair value of our debt approximated $1.56 billion and $1.63 billion as of June 30, 2022  and December 31, 2021, respectively. These fair value amounts were estimated using an income approach by applying market interest rates for comparable instruments and developed based on inputs classified as Level 2.
The weighted average interest rates on long-term debt, excluding finance leases were as follows:
Six Months Ended
June 30, 2022
Twelve Months Ended December 31, 2021
$1.2 billion Credit Facility, due in 2026 (variable rate)
3.25 %1.76 %
$200 million term loan, due in 2026 (variable rate)
3.17 %1.40 %
$600 million Senior Notes, due in 2024 (fixed rate)
5.38 %5.38 %
$500 million Senior Notes, due in 2029 (fixed rate)
3.88 %3.88 %
Promissory notes and deferred consideration (fixed rate)3.39 %3.19 %
Foreign bank debt (fixed rate)9.80 %9.80 %
On April 26, 2022, we entered into a First Amendment which amends, among other provisions, the Credit Agreement to modify the definition of Consolidated EBITDA to add back certain charges in connection with the FCPA Settlement in an aggregate amount not to exceed (i) $61.0 million for the fiscal quarter ended September 30, 2021, (ii) $19.7 million for the fiscal quarter ended December 31, 2021, and (iii) $9.2 million for the fiscal quarter ended March 31, 2022. The Credit Agreement retains, among other covenants, its financial covenant requiring maintenance of a maximum Consolidated Leverage Ratio of 4.25 to 1.00 in any fiscal quarter ending before September 30, 2022 and 4.00 to 1.00 for any fiscal quarter ending on or after September 30, 2022, which includes, among other provisions, continuation of $100.0 million cash add backs to EBITDA through December 31, 2022, with no further add backs thereafter. In April 2022, the Company incurred deferred issuance costs of $0.4 million relating to the First Amendment.
As of June 30, 2022, the Company was in compliance with its financial covenants. The Credit Agreement Defined Debt Leverage Ratio covenant was 4.02 to 1.00, which was below the allowed maximum ratio of 4.25 to 1.00 as set forth in the amended Credit Agreement.
Amounts committed to outstanding letters of credit and the unused portion of the Company’s Credit Facility were as follows:
In millions
June 30, 2022December 31, 2021
Outstanding letters of credit under Credit Facility$61.1 $71.4 
Unused portion of the Credit Facility799.2 881.5 
2022 Q2 10-Q Report
Stericycle, Inc. ●
14

NOTE 6 — INCOME TAXES

The Company reported income tax expense of $8.4 million and $9.1 million for the three months ended June 30, 2022 and 2021, respectively. The effective tax rates for the three months ended June 30, 2022 and 2021, were 44.4% and 23.7%, respectively. The effective tax rate for the three months ended June 30, 2022, reflects (i) losses in jurisdictions that are not eligible for tax benefits on account of valuation allowances, and (ii) equity-based compensation awards expiring without a tax benefit. The effective tax rate for the three months ended June 30, 2021, reflects (i) a tax benefit associated with a matter that was subject to a PFA with the IRS, (ii) losses in jurisdictions that are not eligible for tax benefits on account of valuation allowances and (iii) equity-based compensation awards expiring without a tax benefit.
The Company reported income tax expense of $11.3 million and $22.9 million for the six months ended June 30, 2022 and 2021, respectively. The effective tax rates for the six months ended June 30, 2022 and 2021, were 146.8% and 29.2%, respectively. The effective tax rate for the six months ended June 30, 2022, reflects (i) losses in jurisdictions that are not eligible for tax benefits on account of valuation allowances, and (ii) equity-based compensation awards expiring without a tax benefit. The effective tax rate for the six months ended June 30, 2021, reflects (i) a tax benefit associated with a matter that was subject to a PFA with the IRS, (ii) losses in jurisdictions that are not eligible for tax benefits on account of valuation allowances and (iii) equity-based compensation awards expiring without a tax benefit.
NOTE 7 — EARNINGS (LOSS) PER COMMON SHARE

Basic earnings (loss) per share is computed by dividing Net income (loss) by the number of weighted average common shares outstanding during the reporting period. Diluted earnings per share is calculated to give effect to all potentially dilutive common shares that were outstanding during the reporting period, in the periods in which such effect is dilutive.
The following table shows the effect of stock-based awards on the weighted average number of shares outstanding used in calculating diluted earnings per share:
In millions of shares
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Weighted average common shares outstanding - basic92.1 91.8 92.0 91.7 
Incremental shares outstanding related to stock-based awards (1)
0.1 0.3  0.4 
Weighted average common shares outstanding - diluted92.2 92.1 92.0 92.1 
(1)In periods of net loss, stock-based awards are anti-dilutive and therefore excluded from the earnings (loss) per share calculation.
Anti-dilutive stock-based awards excluded from the computation of diluted earnings (loss) per share using the treasury stock method includes the following:
In thousands of shares
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Option awards1,233 1,958 1,395 2,131 
RSU awards579 8 235 5 
PSUs are offered to key employees and are subject to achievement of specified performance conditions. Contingently issuable shares are excluded from the computation of diluted earnings per share based on current period results. The shares would not be issuable if the end of the reporting period were the end of the contingency period. If such goals are not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed.

2022 Q2 10-Q Report
Stericycle, Inc. ●
15

NOTE 8 — SEGMENT REPORTING

The Company evaluates, oversees, and manages the financial performance of two operating and reportable segments – North America and International.
The following tables show financial information for the Company's reportable segments:
In millions
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Revenues
North America$568.6 $542.6 $1,112.3 $1,076.3 
International111.2 130.1 231.7 264.4 
Total$679.8 $672.7 $1,344.0 $1,340.7 
Adjusted Income from Operations
North America$148.9 $159.6 $283.5 $317.2 
International8.4 15.6 19.8 28.2 
Other Costs(75.3)(69.5)(162.3)(129.7)
Total$82.0 $105.7 $141.0 $215.7 

The following table reconciles the Company's primary measure of segment profitability, Adjusted Income from Operations, to Income from operations:
In millions
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Total Reportable Segment Adjusted Income from Operations$82.0 $105.7 $141.0 $215.7 
Adjusting Items:
ERP Implementation(3.5)(17.3)(9.1)(35.2)
Intangible Amortization(30.8)(30.1)(63.2)(59.9)
Portfolio Optimization (0.4)(1.3)(1.6)
Litigation, Settlements and Regulatory Compliance(9.6)(2.3)(23.4)(4.3)
Income from operations$38.1 $55.6 $44.0 $114.7 

NOTE 9 — COMMITMENTS AND CONTINGENCIES
Legal Proceedings
The Company operates in highly regulated industries and responds to regulatory inquiries or investigations from time to time that may be initiated for a variety of reasons. At any given time, the Company has matters at various stages of resolution with the applicable government authorities. The Company is also routinely involved in actual or threatened legal actions, including those involving alleged personal injuries and commercial, employment, environmental, tax, and other issues. The outcomes of these matters are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, claimants seek damages, as well as other relief, including injunctive relief, that could require significant expenditures or result in lost revenue.
In accordance with applicable accounting standards, the Company establishes an accrued liability for loss contingencies related to legal and regulatory matters when the loss is both probable and reasonably estimable. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is not probable or a probable loss is not reasonably
2022 Q2 10-Q Report
Stericycle, Inc. ●
16

estimable, no liability is recorded. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. These accruals represent management’s best estimate of probable losses and, in such cases, there may be an exposure to loss in excess of the amounts accrued. Estimates of probable losses resulting from litigation and regulatory proceedings are difficult to predict. Legal and regulatory matters inherently involve significant uncertainties based on, among other factors, the jurisdiction and stage of the proceedings, developments in the applicable facts or law, and the unpredictability of the ultimate determination of the merits of any claim, any defenses the Company may assert against that claim, and the amount of any damages that may be awarded. The Company’s accrued liabilities for loss contingencies related to legal and regulatory matters may change in the future as a result of new developments, including, but not limited to, the occurrence of new legal matters, changes in the law or regulatory environment, adverse or favorable rulings, newly discovered facts relevant to the matter, or changes in the strategy for the matter. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.
Contract Class Action and Opt Out Lawsuits. Beginning on March 12, 2013, the Company was served with several class action complaints filed in federal and state courts in several jurisdictions. These complaints asserted, among other things, that the Company had imposed unauthorized or excessive price increases and other charges on its customers in breach of its contracts and in violation of the Illinois Consumer Fraud and Deceptive Business Practices Act. The complaints sought certification of the lawsuit as a class action and the award to class members of appropriate damages and injunctive relief. These related actions were ultimately transferred to the United States District Court for the Northern District of Illinois for centralized pretrial proceedings.
The parties engaged in discussions through and overseen by a mediator regarding a potential resolution of the matter and reached a settlement agreement, as previously disclosed, which settlement agreement obtained court approval on March 8, 2018. Under the terms of the SQ Settlement, the Company admitted no fault or wrongdoing whatsoever, and it entered into the SQ Settlement to avoid the cost and uncertainty of litigation.
Certain class members who have opted out of the SQ Settlement have filed lawsuits against the Company, and the Company is defending and intends to resolve those actions. The Company has made an accrual in respect of these collective matters consistent with its accrual policies described above, which is not material.
Government Investigations. On June 12, 2017, the SEC issued a subpoena to the Company, requesting documents and information relating to the Company’s compliance with the FCPA or other foreign or domestic anti-corruption laws with respect to certain of the Company’s operations in Latin America. In addition, the DOJ notified the Company that it was investigating this matter in parallel with the SEC. The Company is cooperating with these agencies and certain foreign authorities. The Company also conducted an internal investigation of these and other matters, including outside of Latin America, under the oversight of the Audit Committee of the Board of Directors and with the assistance of outside counsel.
As previously disclosed, the Company has engaged in settlement discussions in connection with the foregoing government investigations. On April 20, 2022, the Company announced that it has settled these matters with the DOJ and the SEC. Under the Company's settlement with the DOJ, the Company entered into a deferred prosecution agreement (“DPA”) with the DOJ, under which the DOJ agreed to defer criminal prosecution of the Company for a period of three years for charges of conspiring to violate the anti-bribery and books and records provisions of the FCPA. If the Company remains in compliance with the DPA during its three-year term, the deferred charge against the Company would be dismissed with prejudice. The Company agreed to pay $52.5 million in criminal fines to the DOJ, subject to offsetting up to $17.5 million of that amount based upon fines paid to Brazilian authorities (as described below). Under the Company’s settlement with the SEC, the Company entered into an administrative resolution with the SEC with respect to violations of the anti-bribery, books and records and internal controls provisions of the FCPA, and agreed to disgorge $22.2 million and pay pre-judgment interest of $6.0 million to the SEC. $4.2 million of the amount to be disgorged is subject to offset based upon amounts paid in disgorgement to Brazilian authorities (as described below). In addition, under the settlements with the DOJ and with the SEC, the Company will engage an independent compliance monitor for two years and undertake compliance with self-reporting obligations for an additional year.
Also as announced on April 20, 2022, the Company reached a settlement agreement with the Brazilian Controladora-General da Uniao (CGU) and Advocacia-General da Uniao (Attorney General Office) in the amount of $23.1 million, $13.5 million of which will offset amounts that would otherwise be paid to the DOJ and the SEC.
2022 Q2 10-Q Report
Stericycle, Inc. ●
17

Based on the foregoing settlements and as provided by U.S. GAAP, in addition to the $80.7 million previously accrued in 2021, the Company accrued an additional $9.6 million in the first half of 2022 for the FCPA Settlement. In the second quarter of 2022, the Company paid $75.8 million of the agreed settlement to the DOJ, the SEC and the Brazilian authorities.
The Company is also discussing potential settlement of a related investigation with an additional Brazilian authority. Because this negotiation is ongoing, the Company cannot predict with certainty its outcome, including whether a settlement will be reached, the amount of any potential monetary payments, or injunctive or other relief. In the event the Company negotiates a settlement with this Brazilian authority, certain monetary portions of the agreement with the DOJ may be offset by payments made thereto. At the present time, the Company is unable to reasonably estimate nor provide any assurance regarding the amount of any potential loss in excess of the amount accrued relating to these matters.
In addition, the Company has been informed that the office of the United States Attorney for the Southern District of New York is conducting an investigation into compliance with the False Claims Act and other federal statutes in connection with the collection, transportation and disposal of hazardous waste by the Company’s former ESOL business unit. The Company has also been informed that the State of California Department of Justice is conducting an investigation related to the Company’s collection, transportation, and disposal of waste generated by government customers in California. The Company is cooperating with these investigations.
The Company has not accrued any amounts in respect of the investigation matters set forth in the preceding paragraph, as it cannot estimate any reasonably possible loss or any range of reasonably possible losses that the Company may incur. The Company is unable to make such an estimate because, based on what the Company knows now, in the Company’s judgment, the factual and legal issues presented in these matters are sufficiently unique that the Company is unable to identify other circumstances sufficiently comparable to provide guidance in making estimates.
Environmental and Regulatory Matters. The Company is subject to various federal, state and local laws and regulations. In the ordinary course of business, we are routinely involved in government enforcement proceedings, private lawsuits, and other matters alleging non-compliance by the Company with applicable law. The issues involved in these proceedings generally relate to alleged violations of existing permits or other requirements, or alleged liability due to our current operations, pre-existing conditions at the locations where we operate, and/or successor or predecessor liability associated with our portfolio optimization strategy. From time to time, the Company may be subject to fines or penalties in regulatory proceedings relating primarily to waste treatment, storage or disposal facilities.
Effective April 6, 2020, the Company completed the divestiture of its Domestic Environmental Solutions business, including the facility in Rancho Cordova, California, to Harsco Corporation. Pursuant to the Purchase Agreement, the Company may have liability under certain indemnification claims for matters relating to those Environmental Solutions facilities, including potentially with respect to the investigations by the Southern District of New York and California Department of Justice described above and the Rancho Cordova, California, and DEA Investigation matters discussed below.
Rancho Cordova, California, NOVs. On June 25 and 26, 2018, the California DTSC conducted a Compliance Enforcement Inspection of the Company’s former Environmental Solutions facility in Rancho Cordova, California. On February 14, 2020, DTSC filed an action in the Superior Court for the State of California, Sacramento County Division, alleging violations of California’s Hazardous Waste Control Law and the facility’s hazardous waste permit arising from the inspection. That action is ongoing.
The Company has not accrued any amounts in respect of this matter and cannot estimate the reasonably possible loss or the range of reasonably possible losses that it may incur. The Company is unable to make such an estimate because (i) litigation is by its nature uncertain and unpredictable and (ii) in the Company’s judgment, the factual and legal allegations asserted by DTSC are sufficiently unique that it is unable to identify other proceedings with circumstances sufficiently comparable to provide guidance in making estimates.
Rancho Cordova, California, Permit Revocation. Separately, on August 15, 2019, the Company received from DTSC a written Intent to Deny Hazardous Waste Facility Permit Application for the Rancho Cordova facility. Following legal challenges, that DTSC action became final as of April 8, 2022, triggering an obligation to execute the closure plan set forth in the facility's permit. Consistent with its accrual policies described previously, the Company has made an
2022 Q2 10-Q Report
Stericycle, Inc. ●
18

accrual in the amount of its estimate of closure costs reasonably likely to be incurred and indemnified to Harsco under the Purchase Agreement, which is not material.
DEA Investigation. On February 11, 2020, the Company received an administrative subpoena from the DEA, which executed a search warrant at the Company’s former Environmental Solutions facility at Rancho Cordova, California and an administrative inspection warrant at the Company’s former facility in Indianapolis, Indiana for materials related to the former Environmental Solutions business of collecting, transporting, and destroying controlled substances from retail customers (the “ESOL Retail Controlled Substances Business”). On that same day, agents from the DTSC executed a separate search warrant at the Rancho Cordova facility. Since that time, the U.S. Attorney’s Office for the Eastern District of California (“USAO EDCA”) has been overseeing criminal and civil investigations of the ESOL Retail Controlled Substances Business. The USAO EDCA has informed the Company that it may have civil liability under the Controlled Substances Act related to the Domestic Environmental Solutions Retail Controlled Substances Business. The Company is cooperating with the civil and criminal investigations, which are ongoing.
The Company has not accrued any amounts in respect of these investigations and cannot estimate the reasonably possible loss or any range of reasonably possible losses that the Company may incur. The Company is unable to make such an estimate because, based on what the Company knows now, in the Company’s judgment, the factual and legal issues presented in this matter are sufficiently unique that the Company is unable to identify other circumstances sufficiently comparable to provide guidance in making estimates.
European Retrovirus Investigations. In conjunction with Europol, governmental authorities of Spain, Portugal, and Romania have conducted coordinated inspections of a large number of medical waste management facilities, including Stericycle facilities, relating to the transportation, management and disposal of waste that may be infected with the COVID-19 virus, and related matters. The inspections have resulted in proceedings in Spain and Portugal. The Company intends to vigorously defend itself in these proceedings.
The Company has not accrued any amounts in respect of these investigations, as it cannot estimate the reasonably possible loss or any range of reasonably possible losses that the Company may incur. The Company is unable to make such an estimate because, based on what the Company knows now, in the Company’s judgment, the factual and legal issues presented in this matter are sufficiently unique that the Company is unable to identify other circumstances sufficiently comparable to provide guidance in making estimates.
2022 Q2 10-Q Report
Stericycle, Inc. ●
19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Safe Harbor Statement
This document may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. When we use words such as “believes”, “expects”, “anticipates”, “estimates”, “may”, “plan”, “will”, “goal”, or similar expressions, we are making forward-looking statements. Forward-looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of our management about future events and are therefore subject to risks and uncertainties, which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Factors that could cause such differences include, among others, inflationary cost pressure in labor, supply chain and other expenses, decreases in the volume of regulated wastes or personal and confidential information collected from customers, the ability to implement the remaining phases of our ERP system, and disruptions resulting from deployment of our ERP system, disruptions in our supply chain, disruptions in or attacks on information technology systems, developments in the COVID-19 pandemic and the resulting impact on the results of operations, long-term remote work arrangements which may adversely affect our business, measures taken by governmental authorities to prevent the spread of the COVID-19 virus which could disrupt our supply chain, result in disruptions in transportation services and restrictions on the ability of our team members to travel, result in temporary closure of our facilities or the facilities of our customers and suppliers, affect the volume of paper processed by our secure information destruction business and the revenue generated from the sale of SOP, labor shortages, an economic disruption in the U.S. and other countries resulting from the COVID-19 virus, changing market conditions in the healthcare industry, competition and demand for services in the regulated waste and secure information destruction industries, SOP pricing volatility, foreign exchange rate volatility in the jurisdictions in which we operate, changes in governmental regulation of the collection, transportation, treatment and disposal of regulated waste or the proper handling and protection of personal and confidential information, the level of government enforcement of regulations governing regulated waste collection and treatment or the proper handling and protection of personal and confidential information, charges related to portfolio optimization or the failure of acquisitions or divestitures to achieve the desired results, failure to consummate transactions with respect to non-core businesses, the obligations to service substantial indebtedness and comply with the covenants and restrictions contained in our credit agreements and notes, a downgrade in our credit rating resulting in an increase in interest expense, political, economic, inflationary and other risks related to our foreign operations, the outcome of pending, future or settled litigation or investigations including with respect to the U.S. Foreign Corrupt Practices Act and foreign anti-corruption laws, weather and environmental changes related to climate change, requirements of customers and investors for net carbon zero emissions strategies, and the introduction of regulations for greenhouse gases, which could negatively affect our costs to operate, failure to maintain an effective system of internal control over financial reporting, as well as other factors described in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Forms 10-Q. As a result, past financial performance should not be considered a reliable indicator of future performance, and investors should not use historical trends to anticipate future results or trends. We disclaim any obligation to update or revise any forward-looking or other statements contained herein other than in accordance with legal and regulatory obligations.

Overview
Stericycle is a global business-to-business services company. We provide an array of highly specialized solutions that protect the health and well-being of the people and places around us in a safe, responsible, and sustainable way. Since our founding in 1989, we have grown from a small start-up in medical waste management into a leader across a range of increasingly complex and highly regulated arenas, serving healthcare organizations and commercial businesses of every size through RWCS and SID.

2022 Q2 10-Q Report
Stericycle, Inc. ●
20


Key business highlights include:
Organic revenues(1) grew 5.0% compared to the second quarter of 2021, with SID organic revenue growing 12.2% and RWCS growing 1.8%.
Pricing levers helped offset labor and other supply chain inflationary cost pressures in the second quarter of 2022. As a result, gross profit margin improved 140 basis points compared to the first quarter of 2022.
Net cash from operating activities increased to a source of funds of $20.4 million in the second quarter of 2022, compared to a use of funds of $38.8 million in the first quarter of 2022.
(1)See Results of Operations, Revenues for a reconciliation between total U.S. GAAP Revenues and Organic Revenues.
COVID-19 Update and Other Developments
Our COVID-19 pandemic response has included efforts to protect the health and well-being of our workforce and our customers. We have worked proactively with the CDC, OSHA, DOT and other regulatory agencies around the world in an attempt to ensure readiness for proper regulated waste management. Our team has demonstrated leadership and commitment to protecting what matters by working with pharmaceutical companies and government agencies to align on standards for secure and compliant COVID-19 vaccination treatment protocols. Additionally, Stericycle supports the front end of vaccination programs through our Communications Solutions service line. We provide scalable patient hotlines, scheduling, and appointment reminders for vaccinations. In March 2022, the Company implemented its global RTO hybrid work schedule applicable to office workers that promotes our value of in person team collaboration while still maintaining our health standards. The Company is continuing to monitor the future implications of COVID-19 and variants and is taking proactive steps to continue to manage the health and safety of team members as they RTO.
Like many organizations, we have been impacted by higher absences related to COVID-variants that surged towards the end of the fourth quarter of 2021 and into the first quarter of 2022, particularly driver and operational team members. Our work force stabilized throughout the first and second quarters of 2022, as the effects of the Delta and Omicron variants on employee absences subsided, but still remains highly susceptible to fluctuations due to various variants that impact sites and regions periodically. Additionally, we have been impacted by driver and operational team member shortages. To date, we are addressing our internal needs through three main areas: (i) recruitment, (ii) market competitive compensation and benefits, and (iii) employee engagement and retention.
Beginning in third quarter of 2021 and continuing throughout the second quarter of 2022, we experienced inflationary cost increases in our underlying expenses, including labor, supply-chain and other costs. We also have been experiencing delays in completing certain capital projects and face additional challenges due to macroeconomic supply chain disruptions. The higher operating labor costs were mainly associated with maintaining competitive wages for existing team members and increased starting wages for new hires. Higher supply chain and other inflationary costs were mainly from higher vehicle rental and maintenance expenses as we continued to experience delays in replacement vehicle deliveries, higher utility expenses, and higher costs associated with supplies and disposable containers and liners. While fuel costs have increased, they have been offset through our existing fuel surcharges.
We have continued to see the impact of the strengthening U.S. Dollar on our foreign currency translation. In the second quarter of 2022, changes in foreign exchange rates unfavorably impacted revenues by $13.7 million.
Stericycle collects and delivers SOP for recycling into paper products to be used in the hospitality industry including napkins, paper towels, and bathroom tissues. Recycled paper tonnage volume for the first half of 2022 was approximately 267,000, which is about 5% lower than the first half of 2021.

Key Business Priorities
In 2022, our five key business priorities remain the following:
Quality of revenue We have been executing against our foundational initiatives to drive revenue quality. These included a formal cross-functional deal review committee, realignment of sales incentive plans, re-organization of our commercial leadership team around our service lines, key customer channels, and implementation of global customer pipeline management processes for both RWCS and SID. As a reminder,
2022 Q2 10-Q Report
Stericycle, Inc. ●
21


our three main pricing levers are as follows: (i) for all multi-year contracts, we adjust pricing at contract anniversary and renewal, (ii) for all new customers and purchasers of our one-time services, we adjust our rates at point of sale, and (iii) for many of our customers, we also have surcharges and fees that provide inflationary cost protection for commodity and other price volatility. Our pricing actions have gained momentum since the first quarter, including our adjustment of surcharges and fees, which provide the most flexible mechanism to help offset inflationary costs by adjusting these surcharges and fees.
Operational efficiency, modernization, and innovation We remain focused on operational efficiency, modernization, and innovation to control variable and discretionary costs and improve performance and efficiencies in our field operations. Our goal is to optimize our facilities with a strategic and standardized operating model. We are analyzing processing capabilities, plant and transportation equipment needs, team member requirements, and potential customer implications or benefits. For example, in the second quarter, we opened new RWCS facilities in the Northeast U.S. and Romania and began constructing a new incineration facility on the U.S. west coast. In addition, we recently installed our new patented SMS Revolution technology in two of our facilities, which increased our Sharps processing capacity and led to at least one shift reduction in both facilities.
ERP Implementation In 2022, we plan to complete pilot ERP system deployments to a subset of North America RWCS. This disciplined and consistent deployment approach allows us to mitigate risk and test data and functionality before deploying the ERP across all RWCS North America customers and facilities. This follows the deployment of our ERP system for North America’s finance and procurement processes and for North America’s SID business that was completed in 2021.
Debt reduction and leverage improvement We expect to improve our leverage ratio through continued focus on operating margin expansion, free cash flow generation, and divestiture proceeds, if applicable. Our amended Credit Facility defined debt leverage ratio was 4.02 times as of June 30, 2022, compared to 3.61 times as of December 31, 2021. Net debt, as defined in the Credit Agreement, and as reported under U.S. GAAP (total U.S. GAAP debt less U.S. GAAP cash and cash equivalents), increased $91.6 million in the first half of 2022, increasing total net debt to approximately $1.7 billion as of June 30, 2022.
Portfolio optimization We expect to continue evaluating opportunities to further optimize our portfolio through a combination of asset rationalizations and strategic accretive tuck-in acquisitions, which streamlines our portfolio of businesses and allows us to focus more deeply on our core businesses.

Certain Key Priorities and Other Significant Matters
The following table identifies certain key priorities and other significant matters impacting our business and how they are classified in the Condensed Consolidated Statements of Income (Loss):
In millions
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Included in SG&A
ERP Implementation$3.5 $17.3 $9.1 $35.2 
Intangible Amortization30.8 30.1 63.2 59.9 
Portfolio Optimization— 0.4 1.3 1.6 
Litigation, Settlements and Regulatory Compliance9.6 2.3 23.4 4.3 
Total included in SG&A$43.9 $50.1 $97.0 $101.0 
After tax items:
Other Tax Matter$— $(5.5)$— $(5.5)
Total after-tax$— $(5.5)$— $(5.5)
2022 Q2 10-Q Report
Stericycle, Inc. ●
22


ERP Implementation
For the periods presented and for the cumulative period since the inception of the ERP Implementation, we have recognized the following, principally reported in Other Costs:
In millions
Three Months Ended June 30,Six Months Ended June 30,Cumulative Since Inception
2022202120222021
ERP Implementation
Consulting and professional fees$3.5 $10.7 $9.1 $22.3 $115.9 
Internal labor— 2.8 — 5.5 39.1 
Software usage/maintenance fees— 3.3 — 6.4 42.3 
Other related expenses— 0.5 1.0 11.5 
Operating expenditures3.5 17.3 9.1 35.2 208.8 
Capital expenditures3.5 9.4 4.1 11.8 184.8 
Total operating and capital expenditures$7.0 $26.7 $13.2 $47.0